Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors

References

• YaoJCHassanMPhanAOne hundred years after “carcinoid:” epidemiology of and prognostic factors for neuroen-docrine tumors in 35,825 cases in the United StatesJ Clin Oncol200826183063307218565894
   PubMed Web of Science ®Google Scholar
• SolorzanoCCLeeJEPistersPWNonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patientsSurgery200113061078108511742342
   PubMed Web of Science ®Google Scholar
• RaymondEDahanLRaoulJLSunitinib malate for the treatment of pancreatic neuroendocrine tumorsN Engl J Med2011364650151321306237
   PubMed Web of Science ®Google Scholar
• YaoJCPhanATChangDZEfficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II studyJ Clin Oncol200826264311431818779618
   PubMed Web of Science ®Google Scholar
• YaoJCLombard-BohasCBaudinEDaily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trialJ Clin Oncol2010281697619933912
   PubMed Web of Science ®Google Scholar
• YaoJCShahMHItoTEverolimus for advanced pancreatic neuroendocrine tumorsN Engl J Med2011364651452321306238
   PubMed Web of Science ®Google Scholar
• YimKLRole of biological targeted therapies in gastroenteropancreatic neuroendocrine tumoursEndocrine201140218118621870172
   PubMed Web of Science ®Google Scholar
• VignotSFaivreSAguirreDRaymondEmTOR-targeted therapy of cancer with rapamycin derivativesAnn Oncol200516452553715728109
   PubMed Web of Science ®Google Scholar
• SabatiniDMmTOR and cancer: insights into a complex relationshipNat Rev Cancer20066972973416915295
   PubMed Web of Science ®Google Scholar
• SmrzDKimMSZhangSmTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cellsBlood2011118266803681322053105
   PubMed Web of Science ®Google Scholar
• ShahTHochhauserDFrowRQuagliaADhillonAPCaplinMEEpidermal growth factor receptor expression and activation in neuroen-docrine tumoursJ Neuroendocrinol200618535536016629834
   PubMed Web of Science ®Google Scholar
• MissiagliaEDalaiIBarbiSPancreatic endocrine tumors: expression profiling evidences a role for Akt-mTOR pathwayJ Clin Oncol201028224525519917848
   PubMed Web of Science ®Google Scholar
• VerhoefSvan Diemen-SteenvoordeRAkkersdijkWLMalignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhoodEur J Pediatr1999158428428710206124
   PubMed Web of Science ®Google Scholar
• YoshidaAHatanakaSOhiYUmekitaYYoshidaHvon Recklinghausen’s disease associated with somatostatin-rich duodenal carcinoid (somatostatinoma), medullary thyroid carcinoma and diffuse adrenal medullary hyperplasiaActa Pathol Jpn199141118478561686137
   PubMedGoogle Scholar
• YimKLCunninghamDTargeted drug therapies and cancerRecent Results Cancer Res201118515917121822826
   PubMedGoogle Scholar
• Grozinsky-GlasbergSFranchiGTengMOctreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell lineNeuroendocrinology200887316818118025810
   PubMed Web of Science ®Google Scholar
• ZitzmannKDe ToniENBrandSThe novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cellsNeuroendocrinology2007851546017310129
   PubMed Web of Science ®Google Scholar
• ThimmaiahKNEastonJHuangSInsulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3′-kinase-Akt signaling pathwaysCancer Res200363236437412543789
   PubMed Web of Science ®Google Scholar
• BeuvinkIBoulayAFumagalliSThe mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translationCell2005120674775915797377
   PubMed Web of Science ®Google Scholar
• FumarolaCLa MonicaSAlfieriRRBorraEGuidottiGGCell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosisCell Death Differ200512101344135715905878
   PubMed Web of Science ®Google Scholar
• O’ReillyKERojoFSheQBmTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktCancer Res20066631500150816452206
   PubMed Web of Science ®Google Scholar
• von WichertGJehlePMHoeflichAInsulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cellsCancer Res200060164573458110969809
   PubMed Web of Science ®Google Scholar
• KirchnerGIMeier-WiedenbachIMannsMPClinical pharmacokinetics of everolimusClin Pharmacokinet2004432839514748618
   PubMed Web of Science ®Google Scholar
• DuranIKortmanskyJSinghDA phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBr J Cancer20069591148115417031397
   PubMed Web of Science ®Google Scholar
• RinkeAMullerHHSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GroupJ Clin Oncol200927284656466319704057
   PubMed Web of Science ®Google Scholar
• PanzutoFDi FonzoMIannicelliELong-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinomaAnn Oncol200617346146616364959
   PubMed Web of Science ®Google Scholar
• ArnoldRRinkeAKloseKJOctreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trialClin Gastroenterol Hepatol20053876177116234004
   PubMed Web of Science ®Google Scholar
• BrunsCJKoehlGEGubaMRapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancerClin Cancer Res20041062109211915041732
   PubMed Web of Science ®Google Scholar
• GubaMvon BreitenbuchPSteinbauerMRapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNat Med20028212813511821896
   PubMed Web of Science ®Google Scholar
• SeeligerHGubaMKleespiesAJauchKWBrunsCJRole of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesisCancer Metastasis Rev2007263–461162117713840
   PubMed Web of Science ®Google Scholar
• LaneHAWoodJMMcSheehyPMmTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitorClin Cancer Res20091551612162219223496
   PubMed Web of Science ®Google Scholar
• YaoJCPhanATFoglemanDRandomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker [abstract]J Clin Oncol201028Suppl 154002
   Web of Science ®Google Scholar
• SaltzLTrochanowskiBBuckleyMOctreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumorsCancer19937212442488389666
   PubMed Web of Science ®Google Scholar
• PollakMNPolychronakosCGuydaHSomatostatin analogue SMS 201–995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-IAnticancer Res1989948898912817814
   PubMed Web of Science ®Google Scholar
• CarracedoAMaLTeruya-FeldsteinJInhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerJ Clin Invest200811893065307418725988
   PubMed Web of Science ®Google Scholar
• VillaumeKBlancMGouysseGVEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/Akt/mTOR pathwayNeuroendocrinology201091326827820389030
   PubMed Web of Science ®Google Scholar
• ZatelliMCPiccinDVignaliCPasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretionEndocr Relat Cancer20071419110217395978
   PubMed Web of Science ®Google Scholar
• PetersennSSchopohlJBarkanAPasireotide (SOM230) demonstrates eff icacy and safety in patients with acromegaly: a randomized, multicenter, phase II trialJ Clin Endocrinol Metab20109562781278920410233
   PubMed Web of Science ®Google Scholar
• KvolsLWiedenmannBObergKSafety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study [abstract]J Clin Oncol200624Suppl 184082
   Web of Science ®Google Scholar